Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...

With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history.

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... growth by minus 8% this quarter, meaning underlying operating profit was ...

On Monday, GSK plc (NYSE:GSK) released headline results ... nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52. Also Read: GSK’s Asthma ...

The update on the GSK-partnered prospect sent Wave’s share ... Circulating wild-type M-AAT protein in plasma reached a mean of 6.9 micromolar at day 15. At that time, the wild-type protein ...